2.915
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat
NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1%Here's Why - MarketBeat
[ARS] Nkarta, Inc. SEC Filing - Stock Titan
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting - Stock Titan
NKTX (Nkarta Inc.) reports wider than expected Q4 2025 loss, shares jump nearly 16 percent on upbeat investor sentiment.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Nkarta cell therapy trial may soon offer outpatient treatment option in AAV - ANCA Vasculitis News
Nkarta (NKTX) Stock Dividend Safety (Underperforming) 2026-04-20Crowd Trend Signals - Xã Thanh Hà
Nkarta (NKTX) Stock: Why It Could Change (In Focus) 2026-04-18Private Capital - Cổng thông tin điện tử Tỉnh Sơn La
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - The Globe and Mail
Nkarta receives FDA agreement for outpatient NKX019 dosing By Investing.com - Investing.com India
Should I buy Nkarta (NKTX) - Zacks Investment Research
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers - Sahm
NKTX: Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway - TradingView
Nkarta announces FDA agreement on outpatient dosing of NKX019 in autoimmune disease, expanding access to community rheumatology centers - marketscreener.com
Nkarta receives FDA agreement for outpatient NKX019 dosing - Investing.com
Nkarta Reports FDA Agreement on Outpatient Dosing of NKX019 - marketscreener.com
Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials - Stock Titan
CEO Moves: Will Nkarta Inc stock benefit from M A2026 Investor Takeaways & Technical Pattern Alert System - baoquankhu1.vn
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Aug PostEarnings: Is Nkarta Inc stock suitable for long term investing2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Nkarta to Participate in Needham Virtual Healthcare Conference - Bitget
Ideas Watch: Does Nkarta Inc have declining or rising EPSGap Down & High Win Rate Trade Tips - baoquankhu1.vn
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Layoff Watch: What analysts say about Nkarta Inc stock2026 Technicals & Real-Time Buy Zone Alerts - baoquankhu1.vn
Is Nkarta (NKTX) Stock Good for Beginners | Price at $2.37, Up 2.16%Most Discussed Stocks - Newser
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
[EFFECT] Nkarta, Inc. SEC Filing - Stock Titan
Nkarta (NASDAQ: NKTX) launches $100M ATM shelf via Stifel as sales agent - Stock Titan
NKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho - Defense World
NKTX PE Ratio & Valuation, Is NKTX Overvalued - Intellectia AI
Mizuho lowers Nkarta stock price target on sales ramp moderation - Investing.com
Mizuho lowers Nkarta stock price target on sales ramp moderation By Investing.com - Investing.com India
HC Wainwright Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX) - MarketBeat
Nkarta files $350M shelf offering, plans $100M ATM stock sale via Stifel - MSN
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
TD Cowen Maintains Nkarta(NKTX.US) With Buy Rating - Moomoo
Risk Hedge: Will Nkarta Inc stock go up in YEARPortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):